P
P

Pfizer

News

Wall Street ends mixed after punishing week

(For a Reuters live blog on U.S., UK and European stock markets, click LIVE/ or type LIVE/ in a news window) * Ross Stores plunges after cutting 2022 forecast * S&P 500 +0.01%, Nasdaq -0.30%, Dow +0.03% (Updates with details at end of session) By Noel Randewich and Amruta Khandekar May 20 (Reuters) - Wall Street ended mixed on Friday after a volati
G
N
P
T
R
U
U

Switzerland buys Pfizer's 19 antiviral Paxlovid

BERLIN, May 20 (Reuters) - Switzerland signed a contract to buy Pfizer's anti-viral drug Paxlovid to treat Covid-19, it said on Friday. The European country said it had signed a contract to buy 12,000 packages and first treatments for certain at-risk patients would start this month. Reporting by Kirsti Knolle, Editing by Miranda Murray
P

British Business - May 11

May 11 (Reuters) - The following are the top stories on the business pages of British newspapers. Reuters has not verified these stories and does not vouch for their accuracy. The Times - Tesla Inc's TSLA.O factory in Shanghai has scaled back production after being hit by supply chain problems, only three weeks after work restarted there. Link - Pf
P
T
T
E

Evonik to invest 8 bln eur by 2030 in high-margin businesses -CEO

* Around 4 bln eur to be invested in Germany * Russia business to come to a standstill * Baby business, C4 unit, Luelsdorf site up for sale BERLIN, May 10 (Reuters) - German chemicals company Evonik EVKn.DE plans to invest 8 billion euros ($8.45 billion) by 2030 to boost growth in its smart materials, specialty additives and nutrition & care units,
P
V

BioNTech's Q1 vaccine sales triple but it still flags full-year decline

FRANKFURT, May 9 (Reuters) - BioNTech's 22UAy.DE first-quarter sales and earnings more than tripled thanks to demand for the COVID-19 vaccine it developed with Pfizer PFE.N , but the German biotech firm is still forecasting a full-year decline in vaccine sales. Quarterly revenues more than tripled from a year earlier to 6.37 billion euros ($6.73 bi
P

Conditions

Popular Assets

Disclaimer: The XM Group entities provide execution-only service and access to our Online Trading Facility, permitting a person to view and/or use the content available on or via the website, is not intended to change or expand on this, nor does it change or expand on this. Such access and use are always subject to: (i) Terms and Conditions; (ii) Risk Warnings; and (iii) Full Disclaimer. Such content is therefore provided as no more than general information. Particularly, please be aware that the contents of our Online Trading Facility are neither a solicitation, nor an offer to enter any transactions on the financial markets. Trading on any financial market involves a significant level of risk to your capital.

All material published on our Online Trading Facility is intended for educational/informational purposes only, and does not contain – nor should it be considered as containing – financial, investment tax or trading advice and recommendations; or a record of our trading prices; or an offer of, or solicitation for, a transaction in any financial instruments; or unsolicited financial promotions to you.

Any third-party content, as well as content prepared by XM, such as: opinions, news, research, analyses, prices and other information or links to third-party sites contained on this website are provided on an “as-is” basis, as general market commentary, and do not constitute investment advice. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, it would be considered as marketing communication under the relevant laws and regulations. Please ensure that you have read and understood our Notification on Non-Independent Investment. Research and Risk Warning concerning the foregoing information, which can be accessed here.

We are using cookies to give you the best experience on our website. Read more or change your cookie settings.

Risk Warning: Your capital is at risk. Leveraged products may not be suitable for everyone. Please consider our Risk Disclosure.